Johnson & Johnson shares weekly forecast: Buyers remain in control as resistance at $273.98 approaches

Traders Union
All News
Stocks
Johnson & Johnson up 0.43% this week

Highlights

Shares of Johnson & Johnson have moved up to $271.92, remaining above key daily moving averages in a bullish structure.
Momentum is strong but appears stretched as indicators approach or enter overbought territory and volatility stands at 2.47%.
The stock is expected to consolidate or grind higher in the $268.96 to $284.67 range, with $267.37 as key support and $273.98 as resistance.

Upbeat earnings and institutional buying drive positive sentiment this week

Johnson & Johnson reported record second-quarter 2026 sales of $25.3 billion, representing 6.6% year-over-year revenue growth, according to Yahoo Finance and ad-hoc-news.de. The company also raised its full-year 2026 revenue and earnings guidance while declaring a dividend of $1.34 per share, with the stock set to go ex-dividend on August 25, 2026. Several institutional investors, including Caitong International Asset Management Co. Ltd and Elyxium Wealth LLC, increased positions in JNJ during the quarter, adding to a supportive corporate backdrop this week.

Momentum stretches higher over the week as technicals approach limits

On the daily chart, the structure favors buyers, supported by an emerging move higher that is not yet confirmed. RSI at 64.28 is approaching overbought, and CCI is already in the overbought zone, suggesting momentum is strong but potentially stretched. Volatility over the past week stands at 2.47%. Nearest support sits at $267.37 and resistance is at $273.98, with the Ichimoku Kijun at $260.98 reinforcing a supportive area below.

Bullish breakout risk rises for next week on technical and range signals

Over the next five trading days, the expected range is $268.96 to $284.67, with a very high probability of an increase and a very low probability of a decrease. The base case is continued consolidation or gradual gains within this range. A bullish breakout above $273.98 would open up room toward the upper end near $284.67. A close below $267.37 would challenge the developing uptrend and put the next support levels in focus.

Jainam Mehta, market strategist, sees Johnson & Johnson maintaining a steady climb this week, with corporate optimism supported by strong earnings and increased institutional positioning. He notes that while momentum remains bullish and technicals stay constructive, overbought signals hint at limited upside unless $273.98 is cleared. Consolidation or gradual gains within the $268.96 to $284.67 window are most likely, as macro and technical dynamics align. "With buyers in control but indicators stretched, I’ll wait for a breakout above resistance or a dip toward support before turning more aggressive this week."

Previously it was reported that Shield Therapeutics achieved higher sales and a reduced loss, signaling continued commercial progress for its core treatment. In comparison, the latest developments for Johnson & Johnson reaffirm positive momentum with upgraded guidance and institutional buying, making the upcoming resistance test near $273.98 a critical level to watch for a potential breakout or pullback.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.